Payment overview · 2025
General Payments
$361.66
22 reported records · 11 companies
Healthcare provider profile · identity verified
Michael S Payne, MD
Allopathic & Osteopathic Physicians|Family Medicine · MT WASHINGTON, KY · NPI 1467554808
Verified facts
What the public records show
CMS Open Payments records show Michael S Payne, MD received $361.66 in general payments during 2025 across 22 reported records.
AstraZeneca Pharmaceuticals LP accounted for 26.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $96.80 | 26.8% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $79.25 | 21.9% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.79 | 9.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $28.15 | 7.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.29 | 6.4% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $21.00 | 5.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.71 | 5.7% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $19.88 | 5.5% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $15.08 | 4.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.52 | 3.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.19 | 2.8% | 4 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $361.66 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $79.25 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $58.81 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.79 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $28.15 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.29 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.29 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.29 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $21.53 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.71 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $19.88 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $15.08 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.19 | 4 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 93 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
37 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
27 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
93 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
69 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 709 | 198 |
| Lisinopril | Lisinopril | 573 | 168 |
| Amlodipine Besylate | Amlodipine Besylate | 540 | 161 |
| Levothyroxine Sodium | Levothyroxine Sodium | 417 | 121 |
| Hydrochlorothiazide | Hydrochlorothiazide | 385 | 112 |
| Atorvastatin Calcium | Atorvastatin Calcium | 362 | 124 |
| Pantoprazole Sodium | Pantoprazole Sodium | 354 | 98 |
| Montelukast Sodium | Montelukast Sodium | 351 | 94 |
| Carvedilol | Carvedilol | 257 | 70 |
| Ezetimibe | Ezetimibe | 245 | 74 |
| Omeprazole | Omeprazole | 237 | 75 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 217 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 195 | 28 |
| Metformin Hcl | Metformin Hcl | 188 | 66 |
| Simvastatin | Simvastatin | 184 | 61 |
| Fluticasone Propionate | Fluticasone Propionate | 180 | 63 |
| Trazodone Hcl | Trazodone Hcl | 178 | 51 |
| Ozempic | Semaglutide | 173 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 172 | 42 |
| Losartan Potassium | Losartan Potassium | 172 | 61 |
| Prednisone | Prednisone | 167 | 133 |
| Valsartan | Valsartan | 148 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 137 | 46 |
| Furosemide | Furosemide | 128 | 46 |
| Gabapentin | Gabapentin | 127 | 29 |
| Potassium Chloride | Potassium Chloride | 116 | 40 |
| Buspirone Hcl | Buspirone Hcl | 115 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 115 | 41 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 98 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 98 | 32 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 93 | 21 |
| Sertraline Hcl | Sertraline Hcl | 88 | 27 |
| Meloxicam | Meloxicam | 87 | 27 |
| Mirtazapine | Mirtazapine | 87 | 33 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 86 | 74 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 27 |
| Allopurinol | Allopurinol | 83 | 25 |
| Alprazolam | Alprazolam | 80 | 12 |
| Alendronate Sodium | Alendronate Sodium | 75 | 21 |
| Eliquis | Apixaban | 69 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 19 |
| Tramadol Hcl | Tramadol Hcl | 68 | 20 |
| Januvia | Sitagliptin Phosphate | 65 | 20 |
| Testosterone Cypionate | Testosterone Cypionate | 64 | suppressed |
| Clonazepam | Clonazepam | 61 | 11 |
| Temazepam | Temazepam | 61 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 61 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 56 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 17 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 50 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 48 | 13 |
| Bupropion Xl | Bupropion Hcl | 46 | 16 |
| Synthroid | Levothyroxine Sodium | 46 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 43 | 35 |
| Valacyclovir | Valacyclovir Hcl | 41 | 22 |
| Atenolol | Atenolol | 39 | 12 |
| Glimepiride | Glimepiride | 39 | 19 |
| Ibandronate Sodium | Ibandronate Sodium | 39 | suppressed |
| Spironolactone | Spironolactone | 39 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 38 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | 12 |
| Pregabalin | Pregabalin | 34 | suppressed |
| Cefdinir | Cefdinir | 33 | 30 |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Ramipril | Ramipril | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Glyburide | Glyburide | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 27 |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 27 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 26 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Fluconazole | Fluconazole | 23 | 14 |
| Levofloxacin | Levofloxacin | 23 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 19 |
| Azithromycin | Azithromycin | 22 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Nystatin | Nystatin | 17 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Repatha Syringe | Evolocumab | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 13 | 13 |
| Pitavastatin Calcium | Pitavastatin Calcium | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $361.66 · 22 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, FARXIGA, JATENZO, OTEZLA, PREVNAR 20, QULIPTA, REPATHA, TRELEGY ELLIPTA, VOQUEZNA, XYOSTED | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error